Peptide record

TPDB00451

Antibacterial Anticancer Antifungal Antioxidant Antiparasitic Hemolysis Toxicity standard
17 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB00451
Antibacterial Anticancer Antifungal Antioxidant Antiparasitic Hemolysis Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides Functional / health-promoting peptides
AntiBP3 dbAMP DRAMP Peptipedia SATPdb dbACP Antifungipept CAFPdb AODB dbAMP 3.0 i2APP APD_complete APD_hemolytic Hemolytic2 PD_Hemolysis ToxinPred 3.0
standard
No
A 17-aa standard-residue multi-activity (Antibacterial, Anticancer, Antifungal, and other sources) peptide sequence curated from AntiBP3, dbAMP, DRAMP, and other sources, with an available 3D structural model.
Sequence
FFSLIPSLVGGLISAFK
Physicochemical Analysis

Sequence-only estimates for a linear peptide with free termini, not experimentally measured molecular properties. Mass and formula exclude cyclization and disulfide formation. The optical estimates assume paired cysteines, 280 nm, 1 g/L and a 1 cm path. The N-end rule estimate is not a measured plasma half-life.

C89H138N18O21
RNDCEQHMTWY
LFS
1796.18
10.10
1
0
10
+1
-1.50
1.535
137.65
Mammalian: 1.1 hour Yeast: 3 min E.coli: 2 min
0
0.00
3
Residue Composition
number
1
A
0
R
0
N
0
D
0
C
0
E
0
Q
2
G
0
H
2
I
3
L
1
K
0
M
3
F
1
P
3
S
0
T
0
W
0
Y
1
V
Amino Acid Distribution
A: 1 R: 0 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 2 H: 0 I: 2 L: 3 K: 1 M: 0 F: 3 P: 1 S: 3 T: 0 W: 0 Y: 0 V: 1
Chemical Descriptors
17 reviewed residue count
C89H138N18O21 sequence-only estimate (linear, free termini)
1796.18 sequence-only estimate (linear, free termini)
10.10 sequence-only estimate (linear, free termini)
+1 sequence-only estimate (linear, free termini)
-1.50 sequence-only estimate (linear, free termini)
1.535 sequence-only estimate (linear, free termini)
Evidence Records 9 records
Evidence 1 Activity

Activity

% Hemolysis
Hemolysis
0 1 1 0 1 1 3 %
[Ref.29670004]Hemolysis 0% at 1.17 µM, hemolysis 1% at 2.34 µM, hemolysis 1% at 4.69 µM, hemolysis 0% at 9.38 µM, hemolysis 1% at 18.75 µM, hemolysis 1% at 37.50 µM, hemolysis 3% at 75.00 µM against human red blood cell

Source & Reference

Hemolytik APD_complete APD_hemolytic PD_Hemolysis
DRAMP4
Toxins (Basel). 2018 Apr 18 10(4). pii: E161.

Other

Source Activity Label Source Definition
Hemolysis
APD_complete APD-derived hemolytic peptide annotation. APD_hemolytic APD hemolytic peptide annotation. Hemolytik experimentally validated hemolytic peptide annotation.
Evidence 2 Activity

Activity

22% Hemolysis
Toxicity
139.5 µM
Hemolytic Cytotoxic
22% Hemolysis | 139.5 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Structural characterization of a novel peptide with antimicrobial activity from the venom gland of the scorpion Tityus stigmurus: Stigmurin. | Peptides | 2015
Evidence 3 Activity

Activity

50% Cell death
Toxicity
150 µM
Cytotoxic
50% Cell death | 150 | µM | target cell: Vero E6 cells

Target

Vero E6 cells

Source & Reference

NA
DBAASP
Structural characterization of a novel peptide with antimicrobial activity from the venom gland of the scorpion Tityus stigmurus: Stigmurin. | Peptides | 2015
Evidence 4 Activity

Activity

IC50
Toxicity
7.98 µM
Cytotoxic
IC50 | 7.98 | µM | target cell: Mouse fibroblasts NIH 3T3

Target

Mouse fibroblasts NIH 3T3

Source & Reference

NA
DBAASP
Analogs of the Scorpion Venom Peptide Stigmurin: Structural Assessment, Toxicity, and Increased Antimicrobial Activity. | Toxins (Basel) | 2018
Evidence 5 Activity

Activity

3% Hemolysis
Toxicity
75 µM
Hemolytic Cytotoxic
3% Hemolysis | 75 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Analogs of the Scorpion Venom Peptide Stigmurin: Structural Assessment, Toxicity, and Increased Antimicrobial Activity. | Toxins (Basel) | 2018
Evidence 6 Activity

Activity

0% Hemolysis
Toxicity
150 µM
Hemolytic Cytotoxic
0% Hemolysis | 150 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
In silico and in vitro structure-stability-function relationship of analog peptides of Stigmurin and its antibacterial and antibiofilm activities. | Pharmacol Res | 2022
Evidence 7 Activity

Activity

Toxicity
Hemolytic Cytotoxic
Hemolytic_activity: [Ref.29670004]Hemolysis 0% at 1.17 µM, hemolysis 1% at 2.34 µM, hemolysis 1% at 4.69 µM, hemolysis 0% at 9.38 µM, hemolysis 1% at 18.75 µM, hemolysis 1% at 37.50 µM, hemolysis 3% at 75.00 µM against human red blood cell | Cytotoxicity: [Ref.29670004] The cell viability of HeLa cell lines is 56%, 66%, 66%, 81%, 78%, 66% and 30% at peptide concentrations of 2, 4, 8, 10, 15, 20 and 40 µM. ##The cell viability of 3T3 cell lines is 81%, 63%, 51%, 29%, 27%, 19% and 15% at peptide concentra

Target

erythrocytes

Source & Reference

NA
DRAMP
Toxins (Basel). 2018 Apr 18 10(4). pii: E161.
Evidence 8 Activity

Activity

% Hemolysis
Toxicity
7 %
Hemolytic
Hemolytic_activity: [Ref.30709056] 7% hemolysis at 1.2 µg/ml , 4% hemolysis at 2.3 µg/ml , 2% hemolysis at 4.7 µg/ml , 0% hemolysis at 9.4 µg/ml , 3% hemolysis at 18.8 µg/ml , 2% hemolysis at 37.5 µg/ml , 3% hemolysis at 75 µg/ml , 5% hemolysis at 150 µg/ml against human red blood cells

Target

erythrocytes

Source & Reference

NA
DRAMP
Int J Mol Sci. 2019 Jan 31 20(3). pii: E623. doi: 10.3390/ijms20030623.
Evidence 9 Hemolysis

Activity

0 1 1 0 1 1 3 %
% Hemolysis
[Ref.29670004]Hemolysis 0% at 1.17 µM, hemolysis 1% at 2.34 µM, hemolysis 1% at 4.69 µM, hemolysis 0% at 9.38 µM, hemolysis 1% at 18.75 µM, hemolysis 1% at 37.50 µM, hemolysis 3% at 75.00 µM against human red blood cell
Hemolysis

Source & Reference

APD_complete APD_hemolytic PD_Hemolysis
Toxins (Basel). 2018 Apr 18 10(4). pii: E161.
DRAMP4
APD_complete APD_hemolytic PD_Hemolysis

Other

Source Activity Label Source Definition
Hemolysis
APD_complete APD-derived hemolytic peptide annotation. APD_hemolytic APD hemolytic peptide annotation.